GPAT3 (E5R1H) Rabbit mAb #71236
- WB
- IP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 40 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Protocol
Specificity / Sensitivity
GPAT3 (E5R1H) Rabbit mAb recognizes endogenous levels of total GPAT3 protein. Background bands of unknown identity are detected at 20, 70, and 170 kDa.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His289 of human GPAT3 protein.
Background
Glycerol-3-phosphate acyltransferases (GPATs) catalyze the first step in the de novo synthesis of triacylglycerol (TAG) and phospholipids by converting glycerol-3-phosphate to lysophosphatidic acid (LPA) (1). The GPAT family consists of four family members: two mitochondrial proteins (GPAT1 and GPAT2) and two microsomal proteins (GPAT3 and GPAT4). Each can differ in tissue expression, regulation, and physiological and pathophysiological roles (2). The microsomal proteins GPAT3 and GPAT4 were originally designated as AGPAT8 and AGPAT6, respectively. 1-acyl-glycerol-3-phosphate acyltransferase (AGPAT) catalyzes the subsequent reaction converting LPA to phosphatidic acid. The genes were renamed to GPAT3 and GPAT4 upon elucidation of GPAT activity (3,4). Both GPAT3 and GPAT4 are expressed in adipose tissue, but GPAT3 is highly induced during adipocyte differentiation (4). Brown adipose tissue (BAT) preferentially expresses GPAT4 (5). GPAT3 and GPAT4 may also be phosphorylated in response to insulin treatment to increase GPAT activity (6). Accumulation of saturated LPA produced by GPAT4 at the ER-mitochondrial contact site can inhibit autophagy through the abnormal formation of omegasomes, which are precursors to the autophagosome (7). Glycerolipid synthesis by GPAT3 and GPAT4 can also regulate activation of macrophages (8).
- Yamashita, A. et al. (2014) Biology (Basel) 3, 801-30.
- Karasawa, K. et al. (2019) Int J Mol Sci 20, 964. doi: 10.3390/ijms20040964.
- Chen, Y.Q. et al. (2008) J Biol Chem 283, 10048-57.
- Cao, J. et al. (2006) Proc Natl Acad Sci U S A 103, 19695-700.
- Cooper, D.E. et al. (2015) J Biol Chem 290, 15112-20.
- Shan, D. et al. (2010) J Lipid Res 51, 1971-81.
- Shiozaki, Y. et al. (2020) iScience 23, 101105.
- Quiroga, I.Y. et al. (2019) Biochem J 476, 85-99.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.